20 January 2026
The Giustacchini Group of the Genomics Research Centre of Human Technopole has been awarded a €1.66 million grant from the Fondo Italiano per la Scienza (FIS 2) to advance precision immunotherapy for haematological malignancies. The three-year project, titled “Tailoring Precision Immunotherapy to Haematological Malignancies”, aims to develop more effective cell-based therapies for blood cancers by integrating molecular, cellular and systems-level analyses.
Led by Alice Giustacchini, the project will investigate how blood cancers reshape the immune system and how these changes influence the effectiveness of immune cell therapies.
“By capturing the complex interplay between tumour, immune system and therapy, this project will allow us to design cellular treatments that are truly adapted to each disease’s biology.” said Alice Giustacchini.
The project will leverage the five Human Technopole’s National Facilities, enabling integrated analyses across molecular and cellular scales. In addition, the research will be carried out in close collaboration with University College London and Ospedale Pediatrico Bambino Gesù, strengthening international and clinical links.
By bringing together systems-level insight into immune–tumour interactions with translational cell therapy design, this work reflects Human Technopole’s commitment to advancing fundamental discovery with a clear impact on human health. The long-term ambition is to help shape a new generation of immunotherapies that are more precise, effective and tailored to patients’ biological diversity.
